Germany's Stratec H1 revenue falls on service parts, consumables segment decline

Stratec SE

14/08/2026 06:05

Overview
Germany diagnostics systems maker's H1 revenue fell 3.3% at constant currency
Adjusted EPS for H1 declined 17% yr/yr to €0.34
Company confirmed 2026 guidance for sales growth and stable adjusted EBIT margin

Outlook
Stratec confirms 2026 guidance for constant-currency sales growth in medium to high single-digit percent range
Company expects 2026 adjusted EBIT margin to be around 2025 level of 10.0%
Company anticipates most 2026 sales growth to come from strong year-end business

Result Drivers
ANALYZER SYSTEMS DEMAND - Co said H1 sales of Analyzer Systems grew 15.4% at constant currency, driven by higher call-up volumes in immunodiagnostics, molecular diagnostics, and immunohematology
SERVICE PARTS AND CONSUMABLES DECLINE - Co said sales in this segment fell 11.9% at constant currency due to customers' efforts to boost capital efficiency and optimize service costs and stock levels after ownership changes
COST DISCIPLINE AND CURRENCY EFFECTS - Co said improved Q2 profitability was supported by ongoing cost discipline and favorable currency translation, though H1 margin was reduced by negative scale and product mix effects

Company press release: ID:nEQ362Rx0a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
EUR 112.54 mln
 
H1 Adjusted EPS
 
EUR 0.34
 
H1 Adjusted Net Income
 
EUR 4.11 mln
 
H1 ADJ-EBITDA
 
EUR 15.69 mln
 
H1 Adjusted EBIT
 
EUR 7.73 mln
 
H1 Adjusted EBIT Margin
 
6.90%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Stratec Se is €23.00, about 14.1% above its August 13 closing price of €20.15
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads
Aug 12 - Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Aug 13 - Co-Diagnostics Q2 revenue rises slightly amid international expansion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)